Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 27, 2026Journal of the American Chemical Society

Inhalable Polymeric PROTAC Nanococktail for Targeted Protein Degradation in Idiopathic Pulmonary Fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

QTQiaoling TanYZY ZHAOYZY Zhang

Discussion

Loading...

Member takes

Overview

Randomized trial investigates inhalable PROTAC nanococktail efficacy in pulmonary fibrosis, indicating a novel therapeutic approach.

Key Points

  • The research aims to develop an effective inhalable therapy targeting protein degradation in idiopathic pulmonary fibrosis.
  • Developed an inhalable PROTAC nanococktail comprising GAL@SD and FAP@BD nanoparticles.
  • Examined localization and efficacy in a bleomycin-induced mouse model of pulmonary fibrosis.
  • Assessed lung architecture, respiratory function, and collagen deposition post-treatment.
  • The nanococktail restored lung architecture and improved respiratory function compared to single PROTAC nanoparticle (p<0.01).
  • Significantly reduced collagen deposition in treated groups (p<0.001).
  • Reversed fibrosis-associated transcriptional programs, enhancing overall lung health.

Cite This Study

Tan et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6772aea7db3c1953ef04https://doi.org/10.1021/jacs.6c09336
View Full Paper
Ask AI
Bookmark
Share